Skip to main content

Table 2 Proportion of Days Covered (PDC) by index medication, switching pattern and medication gap among DOAC users at 3, 6, 9 and 12 months of follow-up

From: Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?

 

Dabigatran

Rivaroxaban

Apixaban

P-value

3 months

PDC, mean (SD)

0.78 (0.27)

0.81 (0.27)

0.83 (0.25)

<.0001

  ≥ 0.8, n (%)

9196 (61.87)

10,865 (67.89)

5675 (70.25)

 

 0.5–.079, n (%)

2495 (16.79)

2188 (13.67)

1199 (14.84)

 

  < 0.5, n (%)

3173 (21.35)

2952 (18.44)

1204 (14.90)

 

Switching, n (%)

1016 (6.84)

729 (4.55)

255 (3.16)

<.0001

Warfarin

611 (4.11)

414 (2.59)

118 (1.46)

 

Dabigatran

101 (0.63)

23 (0.28)

 

Rivaroxaban

341 (2.29)

114 (1.41)

 

Apixaban

64 (0.43)

214 (1.34)

 

Gap, n (%)

  ≥ 3 days

7276 (48.95)

7055 (44.08)

3662 (45.33)

<.0001

  ≥ 7 days

6026 (40.54)

5770 (36.05)

2892 (35.80)

<.0001

  ≥ 15 days

4953 (33.32)

4689 (29.30)

2262 (28.00)

<.0001

6 months

PDC, mean (SD)

0.67 (0.33)

0.72 (0.32)

0.76 (0.29)

 

  ≥ 0.8, n (%)

7156 (52.57)

8241 (58.49)

4054 (62.97)

 

 0.5–.079, n (%)

2698 (19.44)

2491 (17.68)

1189 (18.47)

 

  < 0.5, n (%)

4023 (28.99)

3358 (23.83)

1195 (18.56)

 

Switching, n (%)

1369 (9.87)

936 (6.64)

321 (4.99)

<.0001

Warfarin

778 (5.61)

523 (3.71)

155 (2.41)

 

Dabigatran

124 (0.88)

24 (0.37)

 

Rivaroxaban

501 (3.61)

142 (2.21)

 

Apixaban

90 (0.65)

289 (2.05)

 

Gap, n (%)

  ≥ 3 days

9511 (68.54)

8924 (63.34)

4230 (65.70)

<.0001

  ≥ 7 days

8334 (60.06)

7645 (54.26)

3520 (54.68)

<.0001

  ≥ 15 days

7029 (50.65)

6402 (45.44)

2829 (43.94)

<.0001

9 months

PDC, mean (SD)

0.61 (0.35)

0.67 (0.34)

0.72 (0.31)

<.0001

  ≥ 0.8, n (%)

5579 (43.36)

6260 (51.68)

2852 (57.70)

 

 0.5–.079, n (%)

2193 (17.04)

1818 (15.01)

839 (16.97)

 

  < 0.5, n (%)

5094 (39.59)

4034 (33.31)

1252 (25.33)

 

Switching, n (%)

1590 (12.36)

990 (8.17)

299 (6.05)

<.0001

Warfarin

884 (6.87)

559 (4.62)

137 (2.77)

 

Dabigatran

121 (1.00)

23 (0.47)

 

Rivaroxaban

600 (4.66)

139 (2.81)

 

Apixaban

106 (0.82)

310 (2.56)

 

Gap, n (%)

  ≥ 3 days

9723 (75.57)

8593 (70.95)

3607 (72.97)

<.0001

  ≥ 7 days

8709 (67.69)

7553 (62.36)

3090 (62.51)

<.0001

  ≥ 15 days

7528 (58.51)

6445 (53.21)

2545 (51.49)

<.0001

12 months

PDC, mean (SD)

0.57 (0.36)

0.64 (0.36)

0.70 (0.33)

<.0001

  ≥ 0.8, n (%)

4761 (40.73)

5080 (49.83)

1969 (56.26)

 

 0.5–.079, n (%)

1587 (13.58)

1284 (12.59)

498 (14.23)

 

  < 0.5, n (%)

5314 (45.69)

3831 (37.58)

1033 (29.51)

 

Switching, n (%)

1717 (14.69)

559 (9.41)

263 (7.51)

<.0001

Warfarin

930 (7.96)

545 (5.35)

121 (3.46)

 

Dabigatran

109 (1.07)

19 (0.54)

 

Rivaroxaban

663 (5.67)

123 (3.51)

 

Apixaban

124 (1.06)

305 (2.99)

 

Gap, n (%)

  ≥ 3 days

9350 (79.99)

7771 (76.22)

2741 (78.31)

<.0001

  ≥ 7 days

8475 (72.50)

6850 (67.19)

2331 (66.60)

<.0001

  ≥ 15 days

7428 (63.55)

5936 (58.22)

1980 (56.57)

<.0001

  1. PDC proportion of days covered, SD standard deviation